Qiagen has launched its Qiagen Clinical Insight bioinformatics content and software platform. The software aims at clinical testing labs that perform next generation sequencing. The platform allows interpreting and reporting on genomic variants identified in the sequencing assays.
The Clinical Insight platform is a potent tool that evaluates genomic variants comparing them with published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical trials. The whole package consists of a software platform, the secure Qiagen Clinical Insight web application and Qiagen’s private data center. Using this set, clinicians will be able to rapidly classify variants, identify treatment options and perform geographical clinical trial matching.
The first two supported applications for the bioinformatics platform are in oncology, for somatic and hereditary cancer testing.
The bioinformatics tools are a must-have in today’s laboratories, where the presence of big data is inevitable. But for the German giant, this software was a logical step that follows its strategic purchase of Enzymatic, a Boston-based company specialized in next generation sequencing.